TR201802943T4 - (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. - Google Patents

(S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. Download PDF

Info

Publication number
TR201802943T4
TR201802943T4 TR2018/02943T TR201802943T TR201802943T4 TR 201802943 T4 TR201802943 T4 TR 201802943T4 TR 2018/02943 T TR2018/02943 T TR 2018/02943T TR 201802943 T TR201802943 T TR 201802943T TR 201802943 T4 TR201802943 T4 TR 201802943T4
Authority
TR
Turkey
Prior art keywords
egfr
treatment
amide
disease
thiazol
Prior art date
Application number
TR2018/02943T
Other languages
English (en)
Turkish (tr)
Inventor
Maria Brachmann Saskia
Fritsch Christine
Maira Sauveur-Michel
René Schnell Christian
Garcia-Echeverria Carlos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR201802943T4 publication Critical patent/TR201802943T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2018/02943T 2010-11-08 2011-11-07 (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. TR201802943T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41111710P 2010-11-08 2010-11-08

Publications (1)

Publication Number Publication Date
TR201802943T4 true TR201802943T4 (tr) 2018-03-21

Family

ID=44947083

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/02943T TR201802943T4 (tr) 2010-11-08 2011-11-07 (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.

Country Status (12)

Country Link
US (4) US20130209461A1 (enExample)
EP (1) EP2637661B1 (enExample)
JP (4) JP2013542228A (enExample)
KR (1) KR101854484B1 (enExample)
CN (2) CN103200943A (enExample)
AU (1) AU2011328227B2 (enExample)
BR (1) BR112013009624A2 (enExample)
CA (1) CA2815492C (enExample)
MX (1) MX360157B (enExample)
RU (1) RU2589695C2 (enExample)
TR (1) TR201802943T4 (enExample)
WO (1) WO2012062694A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017119219A (ru) * 2011-10-14 2018-11-02 Новартис Аг 2-карбоксамид циклоамино производные мочевины в комбинации с ингибиторами hsp90 для лечения пролиферативных заболеваний
MX2014005414A (es) * 2011-11-02 2014-09-22 Novartis Ag Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf).
IN2015DN00450A (enExample) * 2012-08-07 2015-06-26 Novartis Ag
CA2879704A1 (en) * 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US20160030440A1 (en) * 2013-04-05 2016-02-04 Sanofi Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
DK3076969T3 (da) * 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
JP2011506560A (ja) * 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
BR112013009624A2 (pt) 2016-07-12
EP2637661A1 (en) 2013-09-18
CA2815492A1 (en) 2012-05-18
MX360157B (es) 2018-10-24
KR20130143582A (ko) 2013-12-31
CA2815492C (en) 2019-04-09
CN103200943A (zh) 2013-07-10
EP2637661B1 (en) 2017-12-20
WO2012062694A1 (en) 2012-05-18
AU2011328227A1 (en) 2013-04-18
KR101854484B1 (ko) 2018-05-03
JP2013542228A (ja) 2013-11-21
MX2013005182A (es) 2013-07-03
JP2020114849A (ja) 2020-07-30
US20150250778A1 (en) 2015-09-10
RU2589695C2 (ru) 2016-07-10
US20130209461A1 (en) 2013-08-15
CN105412105A (zh) 2016-03-23
JP2016222686A (ja) 2016-12-28
RU2013126485A (ru) 2014-12-20
AU2011328227B2 (en) 2015-04-09
US20200022967A1 (en) 2020-01-23
JP2019048822A (ja) 2019-03-28
US20180325883A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JP7030750B2 (ja) Ｌａｇ－３に対する抗体分子およびその使用
ES2878188T3 (es) Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
ES2732901T3 (es) Moléculas de anticuerpo para TIM-3 y su uso
US20160303127A1 (en) Combination therapy with c-met and egfr antagonists
AU2009221164B2 (en) Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
BR112019020508A2 (pt) anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
JP2020514356A (ja) Ｒｏｓ１キナーゼ阻害剤としての大環状化合物
CN107750164A (zh) 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
RU2481838C2 (ru) Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
CA3060407A1 (en) Treatment of her2 positive cancers
CA3110658A1 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
CN103890007A (zh) 神经调节蛋白抗体及其用途
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
AU2011328227A1 (en) Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
WO2010120592A1 (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
WO2020219926A1 (en) Treatment of cancer with cdk inhibitors
KR20210110664A (ko) Tam 및 met 키나제의 억제제로서의 퀴놀린 화합물
JP2017520609A (ja) 低悪性度漿液性癌におけるｈｅｒ３阻害
US20150010545A1 (en) Methods for treatment of breast cancer nonresponsive to trastuzumab
WO2024254298A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
Sampera Borràs Characterization of molecular mechanisms of acquired resistance to Trastuzumab in gastric cancer
CN122055153A (zh) 用于治疗egfr外显子20突变阳性的肺癌的egfr抑制剂
CN114514032A (zh) 用于治疗癌症的血管紧张素2型(at2)受体激动剂
Mancini Combinatorial strategies to overcome drug resistance in lung cancer